CytoMed Therapeutics Ltd (GDTC)

Price$0.8500Cached quoteAs of 2026-09-10 14:59 UTC

AI: Overvalued

Price checkAt just under one US dollar, the shares look expensive relative to CytoMed's thin cash and tiny sales.

The whole company changes hands for about US$10.6 million, yet cash net of borrowings is only around US$1.3 million, leaving roughly US$9.3 million of value resting on unproven medicines. That is about twelve times annual income of under US$800 thousand, and the stock sits roughly three-quarters below its twelve-month peak. It also trades beneath Nasdaq's one-dollar minimum, a level that eventually forces small companies into rescue moves. Paying today's price requires assuming trial success and painless fundraising - the evidence supports calling it overvalued rather than cheap.

Big pictureCytoMed still loses several dollars for every dollar earned while its experimental cancer treatments advance slowly.

In its latest full year, announced in spring, CytoMed collected US$781 thousand of income from lab services and grants, up from US$664 thousand, yet its audited loss widened to US$3.1 million from US$2.0 million. Even ignoring non-cash share awards and stock-market listing fees, the underlying loss was about US$2.1 million. Singapore's health ministry co-funds the lead trial, which holds research spending down. Today's earnings come from newly acquired cord-blood banking work - useful, but small and lumpy rather than dependable recurring profit.

Business strengthCash reserves are draining fast, so shareholders should expect new share issuance at unfavorable prices soon.

CytoMed's free cash flow - cash left after running and investing in the business - remains deeply negative: operations consumed roughly US$2.9 million last year, and cash nearly halved to US$1.63 million. Offsetting strengths include five owned production buildings across Singapore and Malaysia carrying only US$318 thousand of borrowings, plus cheap regional cost structures. Management says money lasts "at least a year", but a US$50 million registration shelf and a small standing share-sale program mean new issuance at today's depressed price is the likeliest bridge, diluting current holders.

What could change the storyCompleting its first patient trial, securing Malaysian approval, and insider buying could lift the shares quickly.

The bullish case rests on conviction and catalysts: the chairman kept buying even at US$1.50 per share privately, about two-thirds above the market, and six patients have now received its engineered cell therapy in Singapore, with trial completion targeted this year. A Malaysian regulatory submission for its second, unmodified cell therapy was promised by mid-year; official acceptance would broaden the story. The bear case is quieter news flow, a large holder selling, and funding fatigue. Confirmations on either front - or the next cash update - should move the stock hardest.

AI: News

Chairman buys at premiumExecutive chairman Choo Chee Kong paid about two-thirds above market price for privately purchased shares, signaling strong internal confidence.

Over the past three months, chairman Choo Chee Kong bought 112,000 shares privately, then another 200,000 at US$1.50 each - roughly two-thirds above the current quote - lifting his stake to about 24 percent of the company. He also invested S$300,000 (Singapore dollars) of personal money into the LongevityBank subsidiary at a S$5 million valuation. Insiders paying premiums usually reassure outside investors, though these were negotiated blocks from existing holders; the company received none of the cash, and his motives cannot be verified.

Major holder registers share saleOne of the largest early backers filed to sell part of its stake, adding potential overhead supply.

Earlier this month, mDR Ltd - a Singapore-listed vehicle holding over a million shares, more than a tenth of the company - filed a notice of planned sale covering 117,337 shares, worth roughly one hundred thousand dollars at current quotes. That is small beside typical daily trading, and filing a notice does not guarantee selling, but it marks the clearest large-holder exit attempt while the chairman accumulates. Any price impact is uncertain and should not be assumed from timing alone.

Year-end results reveal cash squeezeAnnual results showed a wider loss and sharply lower cash, keeping fundraising questions in focus.

About five months ago the company reported yearly figures: income of US$781 thousand, an audited loss of US$3.1 million, and cash down to US$1.63 million from US$3.9 million a year earlier. Management highlighted government co-funding for its lead trial, five owned facilities, and "at least a year" of resources. Because the trial budget is partly grant-supported, the true test is whether banking-service income grows before cash runs low; the stock has drifted near twelve-month lows since, though causation is unclear.

Company disputes critics' claimsManagement publicly rejected unnamed critics' statements about its research and operations, defending scientific credibility with investors.

Late in the winter, after circulating statements questioned its clinical progress and operations, CytoMed issued a formal denial, confirming its lead engineered cell therapy holds regulatory approval for a first-of-its-kind human trial running at a Singapore public hospital, with six patients treated across two dose levels. For tiny listed companies, credibility battles matter disproportionately because fundraising depends on trust; none of the disputed claims have been independently adjudicated, and the share price reaction around the episode cannot be reliably attributed.

Loading local price history

Revenue

2024

2025

Net income

2022

2023

2024

2025

Free cash flow

2022

2023

2024

2025

Total cash / debt

CashTotal debt

2021

2022

2023

2024

2025

Financial statements

	2025	2024	2023	2022	2021
Revenue	$252,265	$50,872	—	—	—
Research & development	$1.7M	$1.4M	$1.2M	$1.1M	—
Net income	−$3.1M	−$1.8M	−$3.1M	−$2.3M	—
Net profit margin	−1,231.96%	−3,628.51%	—	—	—
Basic EPSper basic share	-$0.27	-$0.16	-$0.29	—	—
Diluted EPSper diluted share	-$0.27	-$0.16	-$0.29	-$0.30	—

Review official source filings ↗

Owners

Reported shareholders

Reference date Jun 30, 2026

Reported holdings Number of shares

View holders

Top 8 reported holders of GDTC
Holder	Shares held
Choo Chee Kong	430.32K
TAN YOONG YING	25.78K
Goh Yvonne	25.78K
Axiom Investment Management LLC	7.03K
UBS Group AG	4.83K
Toh Keng Kiat	4K
Yew Chak Hua	2.47K
OSAIC HOLDINGS, INC.	21

Bars compare reported share counts. A matching total for this share class and reporting period is unavailable, so percentages are not shown.

Source: SEC Form 4 ↗Updated Sep 29, 2026 · Quarterly data

Insider buys & sells

Jul 1, 2024–Jun 30, 2026

Buys1$128.8K disclosed value

Sells (SEC code S)0$0.00 disclosed value

Transaction	Insider	Type	Shares	Price	Value	Owned after
May 13, 2026Form 4	Choo Chee KongDirector,TenPercentOwner	BuyOrdinary Shares, no par value per share	112.0K	$1.15	$128.8K	430.3K

Review ownership filings at SEC.gov ↗

Community posts

View community

It’s quiet here.

No posts about GDTC yet. Start the conversation.

Write the first post

CytoMed Therapeutics Ltd (GDTC)

Financial charts

Financial statements

Owners

Insider buys & sells

Community posts

It’s quiet here.